Amar Manvar

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
267 Background: Guidelines recommend intravesical chemotherapy and immunotherapy in the management of non-muscle-invasive bladder cancer (NMIBC) to reduce the risks of recurrence and potentially progression. Nevertheless, recent claims-based analyses have suggested exceedingly low rates of utilization of some of these therapies in practice. In general,(More)
The development of pelvic abscesses is a well‐described complication of abdominal and pelvic surgery and is associated with numerous medical conditions including diverticulitis, inflammatory bowel disease, ischemic colitis, and pelvic inflammatory disease.[1] Numerous therapeutic modalities have been described in the literature, including percutaneous,(More)
251 Background: The ideal surveillance regimen for patients with non-muscle-invasive bladder cancer (NMIBC) is uncertain. Given different grade- and stage-specific risks of recurrence and progression, there is some question whether it might be acceptable to pursue less intensive surveillance practices for patients with lower risk disease, and there is a(More)
261 Background: In addition to cytologic evaluation, there are currently four urine-based tests approved by the FDA for bladder cancer detection. At this point, the Guidelines panels from the AUA and EAU do not make specific recommendations about the ideal role of these tests. Furthermore, there is a paucity of data on current patterns of care in this area(More)
  • 1